Plain-English translation of NCT06073769 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world safety study of Onureg® (), a medication taken by mouth to help keep acute myeloid leukemia under control after initial chemotherapy has worked. Researchers are collecting information from Korean patients who are taking this medication as maintenance therapy to make sure it is safe and to understand how it performs in everyday care.
This medication was recently approved in Korea, and the manufacturer is required to monitor its safety in real patients to ensure it continues to work well and cause no unexpected problems over time.
You likely qualify if…
You likely don't qualify if…
As a participant, you will simply continue taking your prescribed maintenance medication while the research team collects safety information from your medical visits and records. The study involves no extra procedures or visits beyond your normal cancer care appointments. Researchers will monitor you over time to track how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
South Korea
Sponsor
Bristol-Myers Squibb
Enrollment target
~154 participants
Started
November 2023
Primary completion
July 2027
Age range
19 Years and older
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
BMS Study Connect Contact Center www.BMSStudyConnect.com
Bristol-Myers Squibb
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.